IL318053A - Self-amplifying rna encoding an influenza virus antigen - Google Patents

Self-amplifying rna encoding an influenza virus antigen

Info

Publication number
IL318053A
IL318053A IL318053A IL31805324A IL318053A IL 318053 A IL318053 A IL 318053A IL 318053 A IL318053 A IL 318053A IL 31805324 A IL31805324 A IL 31805324A IL 318053 A IL318053 A IL 318053A
Authority
IL
Israel
Prior art keywords
self
influenza virus
rna encoding
virus antigen
amplifying rna
Prior art date
Application number
IL318053A
Other languages
Hebrew (he)
Inventor
Hui Cai
Ye Che
Fernando Martin Diaz
Raquel Munoz-Moreno
Quijano Alicia Sol?Rzano
Chong Wang
Original Assignee
Pfizer
Hui Cai
Ye Che
Fernando Martin Diaz
Munoz Moreno Raquel
Quijano Alicia Sol?Rzano
Chong Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Hui Cai, Ye Che, Fernando Martin Diaz, Munoz Moreno Raquel, Quijano Alicia Sol?Rzano, Chong Wang filed Critical Pfizer
Publication of IL318053A publication Critical patent/IL318053A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL318053A 2022-07-10 2023-07-07 Self-amplifying rna encoding an influenza virus antigen IL318053A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263359857P 2022-07-10 2022-07-10
US202263431462P 2022-12-09 2022-12-09
US202363484745P 2023-02-13 2023-02-13
PCT/IB2023/057034 WO2024013625A1 (en) 2022-07-10 2023-07-07 Self-amplifying rna encoding an influenza virus antigen

Publications (1)

Publication Number Publication Date
IL318053A true IL318053A (en) 2025-02-01

Family

ID=87474458

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318053A IL318053A (en) 2022-07-10 2023-07-07 Self-amplifying rna encoding an influenza virus antigen

Country Status (11)

Country Link
US (1) US20240009296A1 (en)
EP (1) EP4551710A1 (en)
JP (1) JP2025522946A (en)
KR (1) KR20250034434A (en)
CN (1) CN119866376A (en)
AU (1) AU2023307581A1 (en)
CA (1) CA3261474A1 (en)
IL (1) IL318053A (en)
MX (1) MX2025000397A (en)
TW (1) TW202417018A (en)
WO (1) WO2024013625A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4661903A1 (en) * 2023-02-09 2025-12-17 Pfizer Inc. Nucleic acids and uses thereof
EP4665390A1 (en) 2023-02-13 2025-12-24 Pfizer Inc. Immunogenic composition against influenza
AU2024342024A1 (en) 2023-09-13 2026-03-26 Pfizer Inc. Immunogenic compositions against influenza
EP4788369A2 (en) 2023-10-06 2026-08-12 Pfizer Inc. Immunogenic compositions
WO2025257691A1 (en) * 2024-06-10 2025-12-18 Seqirus Inc. Potency assay
WO2026029847A1 (en) * 2024-07-29 2026-02-05 Arcturus Therapeutics, Inc. Methods and compositions for pandemic influenza vaccine
WO2026126175A2 (en) 2024-12-15 2026-06-18 Pfizer Inc. Immunogenic compositions against influenza

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
ES2993107T3 (en) * 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
AU2019321186B2 (en) * 2018-08-17 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US11241493B2 (en) * 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
DE202021004130U1 (en) * 2020-02-04 2022-10-26 Curevac Ag Coronavirus Vaccine
CN112546211A (en) * 2020-10-23 2021-03-26 嘉晨西海(杭州)生物技术有限公司 mRNA-based combined vaccine for coronavirus and influenza virus and preparation method thereof
AU2021392077A1 (en) * 2020-12-02 2023-07-13 Seqirus Inc. Multicistronic rna vaccines and uses thereof

Also Published As

Publication number Publication date
JP2025522946A (en) 2025-07-17
EP4551710A1 (en) 2025-05-14
WO2024013625A1 (en) 2024-01-18
CA3261474A1 (en) 2024-01-18
US20240009296A1 (en) 2024-01-11
TW202417018A (en) 2024-05-01
CN119866376A (en) 2025-04-22
KR20250034434A (en) 2025-03-11
MX2025000397A (en) 2025-02-10
AU2023307581A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
CA3261474A1 (en) Self-amplifying rna encoding an influenza virus antigen
IL299169A (en) Self-amplifying sars-cov-2 rna vaccine
CY1124618T1 (en) RECOMBINANT HVT VECTORS EXPRESSING Avian PATHOGEN ANTIGENS AND USES THEREOF
GB2592769B (en) CpG-Adjuvanted SARS-CoV-2 virus vaccine
EP3938379A4 (en) RNA VACCINES AGAINST HIV
EP3568155A4 (en) NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE REACTION AGAINST ZIKA VIRUS
EP4376883A4 (en) RNA VACCINES
PL2121011T3 (en) Vaccines including antigen from four strains of influenza virus
CA3267272A1 (en) Influenza virus vaccines
EP4413144A4 (en) RNA VACCINE LIPIDNANO PARTICLES
IL281299A (en) A method for creating an RNA virus directed against a tumor and for creating mutants of the virus
GB202219228D0 (en) Novel influenza antigens
EP4063383A4 (en) Anti-varicella-zoster virus antibody
ZA202209826B (en) Inactivated sars-cov-2 virus vaccine
EP4011453A4 (en) ONCOLYTIC VACCINE VIRUS
GB202314629D0 (en) Influenza virus vaccines
GB202306220D0 (en) Influenza virus vaccines
KR102211077B9 (en) Pseudo-type rabies vaccine using virus-like particles
AU2024260120A1 (en) Influenza virus vaccines
CA3288324A1 (en) Influenza virus vaccines
HK40122964A (en) Influenza virus vaccines
HK40076791A (en) Hepatitis b virus vaccines
AU2024301059A1 (en) Rna vaccines
AU2023902379A0 (en) RNA vaccines
GB202211076D0 (en) Virus